ZD1839 (IRESSA): a selective EGFR-TK inhibitor.
Ranson, Malcolm R Mansoor, Was
Ranson, Malcolm R
Mansoor, Was
Citations
Altmetric:
Abstract
The recent development of highly selective, target-based cancer therapeutics, such as ZD1839 has resulted from a greater understanding of tumor biology. Amongst the most promising of new target-based agents are inhibitors of the epidermal growth factor receptor. ZD 1839 is a potent, selective epidermal growth factor receptor tyrosine kinase inhibitor that has demonstrated promising results in early clinical trials.
Description
Date
2002-04
Publisher
Collections
Keywords
Type
Article
Citation
ZD1839 (IRESSA): a selective EGFR-TK inhibitor. 2002, 2 (2):161-8 Expert Rev Anticancer Ther